An observational study in Vitiligo, sponsored by Pierre Fabre Dermo Cosmetique. Terminated at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Pierre Fabre Dermo Cosmetique (part of Pierre Fabre) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Vitiligo with a site in France — 8 open to participants now, 14 under way, 6 of them phase 3. Vitiligo · France.
Among the 45 studies in Vitiligo with a site in France, this one is one of 4 that started in 2024, is one of 7 observational ones, and was the 39th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →8 of the 45 studies in Vitiligo with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 9 more countries
Ages 18–99
Incyte Corporation · Sites in France, Argentina, Austria and 11 more countries
Ages 6–11
University Hospital, Bordeaux · Sites in France
Ages 18–65
University Hospital, Tours · Sites in France
Ages 6+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 19 · Phase 3 15
First in 2009; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 114 across 67 observational studies indexed under Vitiligo.
Median enrollment 51 across the 37 interventional studies, 250 across the 7 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pierre Fabre Dermo Cosmetique, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Dermo Cosmetique is the lead sponsor of 59 studies on the registry; 3 are open to participants now.
Pierre Fabre has 1 study filed under Vitiligo — fewer than ten, so there is no comparison to draw.
4 of the studies in Vitiligo with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
| NCT07557693Phase 3Centre Hospitalier Universitaire de NiceMitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo | 2027-09-01 |
| NCT07108283TakedaA Study of Zasocitinib in Adults With Nonsegmental Vitiligo | 2027-03-26 |
| NCT03976622University Hospital, BordeauxAnalysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata | 2027-06-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Vitiligo with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Vitiligo is an autoimmune depigmentation disorder affecting 0.5 to 1% of the population worldwide. Vitiligo lesions are characterized by a progressive loss of pigmentation caused by the disappearance of functioning melanocytes in the epidermis, mainly resulting from the activation of immune cells in a genetically predisposed patient.
Despite major advances in the understanding of the mechanisms of the disease, the treatment remains challenging. Different treatment strategies could lead to cosmetically acceptable repigmentation (>75%), particularly on face and neck. However, after repigmentation, the risk of relapse is estimated at nearly 40% during the first year after stopping treatment.
To date, long-term management remains a challenge. With their topical product RV5098A adapted for patients with vitiligo, Pierre Fabre Laboratories hypothesize that it could be effective in maintaining pigmentation of previously repigmented lesions in adults with facial vitiligo.
Subjects will be enrolled from the investigator's outpatient's reception and/or from the database of the centre. The subjects corresponding to eligibility criteria may receive a phone call, a letter or an e-mail proposing to participate to the clinical study.
Inclusion Criteria:
Criteria related to the population:
- Subject aged between 18 and 75 years included.
Criteria related to the disease:
Criteria related to treatments and/or products:
- Subject responder to a repigmenting treatment
Non-inclusion Criteria:
Criteria related to the diseases / skin condition:
Criteria related to treatments and/or products:
Other: Test product
Other: Control Product
Twice daily applications The product is applied to the entire face.
Twice daily applications The product is applied to the entire face.
Efficacy of the test product RV5098A on the maintenance of pigmentation by the global evolution of facial vitiligo
assessed by the investigator on the face on a 7-point scale (from significant worsening to significant improvement)
Time frame: assessed after 24 weeks of use
Efficacy of the test product RV5098A on the maintenance of pigmentation by the global evolution of facial vitiligo assessed by the investigator
assessed by the investigator on the face on a 7-point scale (from significant worsening to significant improvement)
Time frame: assessed after 12 weeks of use
Efficacy of the test product RV5098A on the maintenance of pigmentation by the global evolution of facial vitiligo assessed by the subject
assessed by the subject on the face on a 7-point scale (from very much worse to very much improved)
Time frame: assessed after 12 and 24 weeks of use and monthly at home
Efficacy of the test product RV5098A on the maintenance of pigmentation by the severity of facial vitiligo by the investigator
assessed by the investigator on the face on a vitiligo severity scale from 0 (absent) to 3 (complete depigmentation)
Time frame: assessed at baseline and after 12 and 24 weeks of use.
Efficacy of the test product RV5098A on the maintenance of pigmentation by the extent of facial vitiligo
assessed by the investigator on the face with score of extent of vitiligo
Time frame: assessed at baseline and after 12 and 24 weeks of use.
Efficacy of the test product RV5098A on the maintenance of pigmentation by the severity of facial vitiligo by the subject
assessed by the subject on the face on a 5-point scale (from no vitiligo to very severe)
Time frame: assessed at baseline, after 12 and 24 weeks of use and monthly at home
Efficacy of the test product RV5098A on the maintenance of pigmentation by the impact on quality of life assessed by the patient
assessed by the subject with quality-of-life questionnaire
Time frame: assessed at baseline, after 12 and 24 weeks of use
Efficacy of the test product RV5098A on the maintenance of pigmentation by imaging quantification.
Measurement of depigmentation surface on a target lesion of the face by the investigator.
Time frame: assessed at baseline, after 12 and 24 weeks of use.
Cosmetic satisfaction and perceived effects as regards to the use of the test product RV5098A by Cosmetic acceptability questionnaire assessed by the patient
A questionnaire with a scale from 0 to 10 responding to statements about the sensorial experience and effect of the product (0=not at all agree, 10=completely agree).
Time frame: assessed after 12 and 24 weeks of use.
Global tolerance of the test product RV5098A assessed by the investigator.
assessed by the investigator with 5-point scale (from bad to excellent)
Time frame: assessed after 24 weeks of use.
Compliance of the subjects to the test product RV5098A
The subject will report his/her compliance in a subject's diary
Time frame: through study completion, 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Oct 2025, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pierre Fabre Dermo Cosmetique →